这意味着这家公司更核实的竞争对手是彭博社(Bloomberg)、Lexis-Nexis【隶属于里德爱思唯尔集团(Reed Elsevier)】,IMS Health和汤普森路透(Thompson-Reuters),而不是斯隆o凯特灵这类专攻癌症研究的机构。
“I think they absolutely can succeed against those who sell information as a service,” Snow said. “That’s the landscape they can prevail in, and that’s the landscape where the incumbents are moving slowly, especially in health.”
斯诺称:“我想该公司肯定能胜过那些信息销售服务商。这将是他们能纵横驰骋的领域,而目前这个领域的巨头进展缓慢,尤其是在医疗健康领域。”
“Flatiron’s trick is they’re little, nimble, and smart,” he said, “and with $100 million, they can probably recruit good talent.” Which is exactly what Turner said he plans to do.
他说:“Flatiron的优势在于他们规模不大,聪明灵活。有了这一个亿,他们可能还能招到更出色的人才。”而这正是特纳的计划。
【科技是否万能 大数据能够战胜癌症吗】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15